Financials in USD. Standardized financial statements.
A compact view of how Genscript Biotech Corporation turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $960.95M | $594.49M | $839.53M | $625.70M | $511.06M | $390.85M | $273.35M | $231.02M | $152.65M | $114.73M |
| Revenue Growth? | +61.6% | -29.2% | +34.2% | +22.4% | +30.8% | +43.0% | +18.3% | +51.3% | +33.0% | 0.0% |
| Cost of Revenue? | $406.92M | $322.36M | $429.98M | $321.62M | $207.58M | $134.95M | $93.06M | $72.48M | $48.06M | $38.51M |
| Gross Profit? | $554.02M | $272.13M | $409.55M | $304.08M | $282.52M | $255.89M | $180.29M | $158.54M | $104.59M | $76.23M |
| Gross Margin? | +57.7% | +45.8% | +48.8% | +48.6% | +55.3% | +65.5% | +66.0% | +68.6% | +68.5% | +66.4% |
| Operating Expenses? | $298.40M | $262.84M | $825.34M | $742.06M | $651.73M | $460.44M | $303.67M | $149.83M | $60.73M | $49.80M |
| Operating Income? | $255.62M | $9.28M | -$415.79M | -$436.04M | -$368.31M | -$204.55M | -$112.10M | $22.43M | $37.46M | $32.52M |
| EBITDA? | $329.77M | $70.04M | -$248.72M | -$355.08M | -$465.78M | -$171.64M | -$92.47M | $35.37M | $45.23M | $37.91M |
| Income Before Tax | -$471.23M | -$170.80M | -$350.98M | -$431.69M | -$517.36M | -$281.90M | -$113.69M | $22.70M | $38.52M | $32.51M |
| Income Tax Expense | $61.96M | $2.98M | $4.14M | -$3.72M | $964,000 | -$477,000 | $3.83M | $1.94M | $11.52M | $5.97M |
| Net Income? | -$533.62M | $2.96B | -$95.48M | -$226.85M | -$358.71M | -$204.94M | -$96.91M | $21.22M | $26.12M | $26.17M |
| EPS? | $-0.25 | $1.40 | $-0.05 | $-0.11 | $-0.18 | $-0.11 | $-0.05 | $0.01 | $0.02 | $0.02 |
| Diluted EPS? | $-0.25 | $1.36 | $-0.05 | $-0.11 | $-0.18 | $-0.11 | $-0.05 | $0.01 | $0.02 | $0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality